Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia
Ruben Mesa, MD
Published: Sunday, Oct 08, 2017
Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.
Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.
Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.
Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.
Diseases like polycythemia vera and essential thrombocythemia are unique, says Mesa, as they are malignancies, but a lot of patients have very long survival. However, some can progress.
Mesa states that the primary goal of the guidelines is the avoidance of thrombosis and bleeding in a risk-based fashion.